[HTML][HTML] Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 …
…, RA Adams, CG Smith, AM Meade, MT Seymour… - The Lancet, 2011 - thelancet.com
Background In the Medical Research Council (MRC) COIN trial, the epidermal growth factor
receptor (EGFR)-targeted antibody cetuximab was added to standard chemotherapy in first-…
receptor (EGFR)-targeted antibody cetuximab was added to standard chemotherapy in first-…
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled …
MT Seymour, TS Maughan, JA Ledermann, C Topham… - The Lancet, 2007 - thelancet.com
Background In the non-curative setting, the sequence in which anticancer agents are used,
singly or in combination, may be important if patients are to receive the maximum period of …
singly or in combination, may be important if patients are to receive the maximum period of …
Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
Purpose: To determine the prevalence and prognostic value of mismatch repair (MMR)
status and its relation to BRAF mutation (BRAF MT ) status in metastatic colorectal cancer (mCRC)…
status and its relation to BRAF mutation (BRAF MT ) status in metastatic colorectal cancer (mCRC)…
[PDF][PDF] Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer
…, S Richman, P Chambers, M Seymour… - J Clin …, 2011 - researchgate.net
Purpose It is uncertain whether modest benefits from adjuvant chemotherapy in stage II
colorectal cancer justify the toxicity, cost, and inconvenience. We investigated the usefulness of …
colorectal cancer justify the toxicity, cost, and inconvenience. We investigated the usefulness of …
[PDF][PDF] KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan …
SD Richman, MT Seymour, P Chambers… - Journal of Clinical …, 2009 - researchgate.net
Purpose Activating mutation of the KRAS oncogene is an established predictive biomarker
for resistance to anti–epidermal growth factor receptor (anti-EGFR) therapies in advanced …
for resistance to anti–epidermal growth factor receptor (anti-EGFR) therapies in advanced …
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from …
…, TS Maughan, RA Adams, MT Seymour… - The Lancet …, 2016 - thelancet.com
Background Patients with peritoneal metastatic colorectal cancer have reduced overall survival
compared with patients with metastatic colorectal cancer without peritoneal involvement. …
compared with patients with metastatic colorectal cancer without peritoneal involvement. …
[HTML][HTML] Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial
MT Seymour, LC Thompson, HS Wasan, G Middleton… - The Lancet, 2011 - thelancet.com
Background Elderly and frail patients with cancer, although often treated with chemotherapy,
are under-represented in clinical trials. We designed FOCUS2 to investigate reduced-dose …
are under-represented in clinical trials. We designed FOCUS2 to investigate reduced-dose …
[HTML][HTML] Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a …
MT Seymour, SR Brown, G Middleton… - The lancet …, 2013 - thelancet.com
Background Therapeutic antibodies targeting EGFR have activity in advanced colorectal
cancer, but results from clinical trials are inconsistent and the population in which most benefit …
cancer, but results from clinical trials are inconsistent and the population in which most benefit …
Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial
PURPOSE Neoadjuvant chemotherapy (NAC) has potential advantages over standard
postoperative chemotherapy for locally advanced colon cancer but requires formal evaluation. …
postoperative chemotherapy for locally advanced colon cancer but requires formal evaluation. …
[HTML][HTML] Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the …
RA Adams, AM Meade, MT Seymour, RH Wilson… - The lancet …, 2011 - thelancet.com
Background When cure is impossible, cancer treatment should focus on both length and
quality of life. Maximisation of time without toxic effects could be one effective strategy to …
quality of life. Maximisation of time without toxic effects could be one effective strategy to …